6533b837fe1ef96bd12a36cf

RESEARCH PRODUCT

“Bevacizumab (BEV),irinotecan (IRI), folinic acid (FA) and fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): the Southern Italy Cooperative Oncology Group (SICOG) experience”

P ComellaB MassiddaD NataleG FilippelliA FarrisG CondemiS TafutoG VessiaG. BarberisSergio Palmeri

subject

Settore MED/06 - Oncologia Medicabevacizumabchemotherapymetastatic colorectal cancerhttp://hdl.handle.net/10447/45273